Start › Rak piersi potrójnie ujemny › Teksas › Houston
Badania kliniczne dla Rak piersi potrójnie ujemny w mieście Houston, TX
42 badań dla Rak piersi potrójnie ujemny szuka uczestników w ośrodkach w mieście Houston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Rekrutacja
- M D Anderson Cancer Center, Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekrutacjaFaza 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekrutacjaFaza 3
- Oncology Consultants P.A. ( Site 0107), Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekrutacjaFaza 3
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Intratumoral N17350 in Advanced Solid Tumors
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekrutacjaFaza 2
- Baylor College of Medicine, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekrutacjaFaza 3
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekrutacjaFaza 1
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekrutacjaBadanie obserwacyjne
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekrutacjaFaza 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekrutacjaFaza 2/3
- (USOR) Texas Oncology, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
RekrutacjaFaza 1
- UT MD Anderson Cancer Center, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekrutacjaFaza 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
RekrutacjaFaza 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
A Study of LY4175408 in Participants With Advanced Cancer
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Study of XB010 in Subjects With Solid Tumors
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekrutacjaFaza 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
RekrutacjaFaza 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RekrutacjaFaza 2
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RekrutacjaFaza 1/2
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RekrutacjaFaza 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RekrutacjaBadanie obserwacyjne
- The University of Texas MD Anderson Cancer Center, Houston
Badania dla Rak piersi potrójnie ujemny w innych miastach
- New York City, NY31 badań
- Nashville, TN28 badań
- Los Angeles, CA27 badań
- Boston, MA26 badań
- San Antonio, TX23 badań
- St. Louis, MO21 badań
- Atlanta, GA20 badań
- Arlington, VA20 badań
- Dallas, TX18 badań
- Chicago, IL16 badań
- Columbus, OH16 badań
- Tampa, FL15 badań
Inne badania w mieście Houston
- Niedrobnokomórkowy rak płuca145 badań
- Rak piersi126 badań
- Nowotwory (wszystkie typy)121 badań
- Nowotwór przerzutowy104 badań
- Rak jelita grubego i odbytnicy102 badań
- Rak jajnika89 badań
- Ostra białaczka szpikowa85 badań
- Rak płuc78 badań
- Rak prostaty76 badań
- Rak endometrium68 badań
- Rak trzustki61 badań
- Czerniak59 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.